Novartis’ Reclast Approved For Fracture Prevention
This article was originally published in The Pink Sheet Daily
Executive Summary
Expanded labeling for the once-yearly osteoporosis treatment follows the launch of DTC ads.
You may also be interested in...
Novartis’ Phase III Bone Drug Reclast Beats Actonel
Company seeks FDA clearance for treatment and prevention of steroid-induced osteoporosis.
Reclast Approved For Once Yearly Treatment Of Postmenopausal Osteoporosis
Zoledronic acid is the only osteoporosis therapy proven to reduce fractures across all key sites, Novartis claims.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.